Close menu

November 5th, 2021 | 11:22 CET

BioNTech, Sativa Wellness, Merck KGaA - Impressive trend

  • Biotechnology
Photo credits:

There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    BioNTech - Plenty of potential

    The latest figures from the Robert Koch Institute show the potential of the vaccine manufacturers' business. According to these figures, only 55.6 million people in Germany have been fully vaccinated. This number corresponds to 66.9% of the population in the Federal Republic. Of these, only 2.4 million people have received a booster vaccination. This topic is likely to represent another significant revenue driver for BioNTech. It is true that the Standing Commission on Vaccination (STIKO) has so far recommended booster vaccinations for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is therefore likely to follow soon.

    Another target group is children between the ages of five and eleven. Good news is now coming from the United States, where BioNTech and Pfizer's COVID-19 vaccine Comirnaty has now received the expected approval of a health authority expert panel, following emergency approval. As of now, the vaccination campaign for nearly 30 million children in the US can begin. In addition to the US, BioNTech and Pfizer have applied for approval of their Corona vaccine for children in Europe in the middle of last month. The EU Medicines Agency (EMA) is expected to come up with a decision soon.

    The stock is currently trading at around USD 295.00, and a breakout above the USD 304.15 level would generate potential to around USD 340.00. Given the above-mentioned next steps, little should stand in the way of a renewed bull run.

    Sativa Wellness - Wide range

    With the legalization of cannabis in several states, the industry faces a prosperous future in the coming years. Add to that the fact that products centered around the cannabis plant will occupy the billion-dollar health and recreational sectors in the next wave. Sativa Wellness, a Canadian company with operations in the UK, plans to become one of the big players in producing and distributing high-quality CBD products and CBD services in Europe.

    In doing so, Sativa Wellness' business model stands on three legs that run entirely separately from each other. Under Goodbody Botanicals, CBD products developed on a gold standard basis are produced for the end consumer. In a strictly regulated European health segment, PhytoVista has also become one of the top three CBD and hemp testing laboratories on the continent. The third brand, Goodbody Wellness, offers testing services for clinics and direct-to-consumer and direct-to-business services via a telemedicine consulting service.

    The opening of the 70th Goodbody clinic was announced here. The "Virtual GP Service" offers all of its customers the ability to follow up on their wellness test results with a virtual medical consultation. Now the plan is to develop a portfolio of private healthcare services. With the rapidly growing network of clinics, access to physician consultations is the next logical step in offering a complete wellness solution.

    After a management change and complete realignment, the new structure is already taking full effect. Sales exploded by 828% to EUR 4.17 million in the second quarter compared to the same quarter last year. Gross profit increased by 804% to EUR 2.29 million compared to the same quarter in 2020. The gross margin here was 55%. Sativa is on a good path and is setting an impressive pace to significantly increase the currently still manageable stock market value of EUR 16.48 million.

    Merck - The vaccine profiteer

    Even in the BioNTech haze, companies can continue to profit due to the Corona pandemic. The following success story comes from Darmstadt, where Merck KGaA is based. The DAX-listed Company works closely with BioNTech and supplies urgently needed lipids to Mainz. The lipids are used in the production of the COVID-19 vaccine Comirnaty and are essential for the drug release of mRNA therapeutics in the body. They enable a vaccine to exert its effect.

    Based on the solid third quarter, the pharmaceutical and specialty chemicals group has raised its full-year forecasts again. The last increase in the outlook was in August of this year. Full-year sales are expected to grow from EUR 19.30 billion to EUR 19.85 billion, up from EUR 17.5 billion in 2020. Previous estimates were EUR 18.80 billion to EUR 19.70 billion. Earnings before interest, taxes, depreciation and amortization adjusted for special items are expected to grow from EUR 5.2 billion in the previous year to EUR 6.0 to 6.3 billion. The previous forecast was EUR 5.6 to 6.0 billion.

    The full set of figures for the Darmstadt-based Company will be published on November 11. Following the figures, the British investment bank Barclays took the floor and reiterated its "overweight" rating with a target price of EUR 215.

    The pandemic will accompany society for a while yet. Booster vaccinations provide recurring revenue for vaccine makers such as BioNTech and those around them such as pharmaceutical and specialty chemicals group Merck. The CBD market is growing rapidly. The Sativa Wellness Group is well-positioned in this regard and has long-term potential.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.


    Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

    MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

    • Biotechnology
    • Pharma

    2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.


    Commented by Fabian Lorenz on November 23rd, 2023 | 07:40 CET

    Buy now? Morphosys, Siemens Energy and Desert Gold share

    • Mining
    • Gold
    • renewableenergies
    • Biotechnology

    What do renewable energies, biotech and gold have in common? Shares from these sectors have predominantly experienced significant losses in 2023. Morphosys, Siemens Energy and Desert Gold are examples of this. However, the underperformers in the current year are often among the top performers in the upcoming year. Can this apply to these three shares? In the case of Morphosys, the latest study data has been confusing, and the share has given back its gains of the year. Analysts are now expressing their views. Siemens Energy has lost over 30% of its value due to operational problems, and the price targets of the experts vary widely. Explorer Desert Gold has been quiet recently. Is it the calm before a price jump? In any case, the share is anything but expensive.